Investors should monitor for Phase 1b data readout in summer 2026, which could provide critical efficacy and safety data for CRB-913 and potentially impact valuation if results meet or exceed the 2.9% placebo-adjusted weight loss observed in Phase 1a
Price Chart
Executive Summary
Corbus Pharmaceuticals announced the last patient has completed their first visit in the CANYON-1 Phase 1b clinical trial of CRB-913 for obesity treatment, with study completion expected in summer 2026. The trial is a 16-week, double-blind, placebo-controlled study in 240 participants evaluating multiple dose levels.
Key Facts
- Last patient first visit achieved in CANYON-1 Phase 1b clinical trial for CRB-913 in obesity
- CANYON-1 is a 16-week, double-blind, placebo-controlled, dose-ranging study with 240 obese, non-diabetic participants
- Trial includes placebo cohort and three CRB-913 dose cohorts (20 mg, 40 mg, 60 mg) administered orally once daily
- Study is on track for completion in summer 2026
- CRB-913 is a once-daily, highly peripherally restricted oral CB1 inverse agonist
Financial Impact
No immediate financial impact disclosed
Risk Factors
- Clinical trial may not replicate Phase 1a results
- Potential safety or tolerability issues could emerge in larger study
- Competitive landscape in obesity treatment remains challenging with established GLP-1 therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-153923 |
| Document: crbp-ex99_1.htm | 0001193125-26-153923 |
| Document: 0001193125-26-153923-index-headers.html | 0001193125-26-153923 |
| Document: 0001193125-26-153923-index.html | 0001193125-26-153923 |
| Document: 0001193125-26-153923.txt | 0001193125-26-153923 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 8-K | $4.33 | awaiting T+60 | — | $4.15 (−4.16%) |
Sep 30, 2026 27d ago | SC 13G | $6.34 | awaiting T+60 | — | $4.15 (−34.54%) |
Sep 22, 2026 5w ago | Institutional Cluster | $7.88 | awaiting T+60 | — | $4.15 (−47.30%) |
Sep 14, 2026 6w ago | 8-K | $8.08 | awaiting T+60 | — | $4.15 (−48.64%) |
Sep 11, 2026 6w ago | Press Release | $8.08 | awaiting T+60 | — | $4.15 (−48.64%) |
Aug 12, 2026 10w ago | Insider Cluster | $10.08 | awaiting T+60 | — | $4.15 (−58.83%) |
Aug 10, 2026 11w ago | Insider Cluster | $9.51 | awaiting T+60 | — | $4.15 (−56.36%) |
May 26, 2026 22w ago | 8-K | $7.91 $9.99 | ▲ +26.30% | ▲ +23.57% | $4.15 (−47.53%) |
May 21, 2026 22w ago | 8-K | $11.51 $10.49 | ▼ −8.86% | ▼ −13.16% | $4.15 (−63.94%) |
May 14, 2026 23w ago | 8-K | $11.98 $9.46 | ▼ −21.04% | ▼ −24.62% | $4.15 (−65.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers